<DOC>
	<DOCNO>NCT00693862</DOCNO>
	<brief_summary>The purpose study show high minimum concentration value obtain follow repeat dos Stalevo 4 time daily compare lecodopa/carbidopa treatment correspond dose regimen .</brief_summary>
	<brief_title>Pharmacokinetic Study With Repeated Doses Stalevo</brief_title>
	<detailed_description />
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Entacapone</mesh_term>
	<criteria>Written inform consent obtain Male female patient idiopathic Parkinson 's disease either stable drug response mild predictable endofdose wearingoff symptom . Hoehn Yahr stage 12.5 perform `` ON '' state . Treatment 35 daily dos levodopa/DDCI ± entacapone total daily levodopa dose range 300600 mg . Unchanged levodopa/DDCI ± entacapone antiparkinsonian medication ( dopamine agonist , monoamine oxidase B ( MAOB ) inhibitor , amantadine and/or anticholinergic dos recommend manufacturer ) , , least 2 week prior first treatment period . Age within 3072 year , inclusive . Secondary atypical parkinsonism . Patients moderate mark wearingoff symptom unpredictable `` OFF '' period . Patients treatmentrelated peakdose dyskinesia . Change dose strength , daily dose dose frequency medicinal product use treat medical condition Parkinson 's disease within 2 week . Use iron preparation chelate agent . Patients history laboratory abnormality consistent , clinically significant cardiovascular , pulmonary , gastrointestinal , hepatic , renal , neurological psychiatric disorder major concurrent illness , may influence outcome study . History neuroleptic malignant syndrome ( NMS ) and/or nontraumatic rhabdomyolysis , malignant melanoma , narrowangle glaucoma pheochromocytoma . Any abnormalities laboratory value , vital sign electrocardiogram ( ECG ) clinical relevance . Patients use antiparkinsonian drug rescue medication ( include soluble levodopa formulation ) . Concomitant treatment apomorphine , MAOA inhibitor nonselective MAO inhibitor . Known hypersensitivity active substance excipients study drug . Participation drug study within 60 day prior study entry Unsuitable vein repeat venopuncture . Blood donation loss significant amount blood within 60 day prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>72 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Focus study pharmacokinetics study drug</keyword>
</DOC>